1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Evogene Ltd.
  6. News
  7. Summary
    EVGN   IL0011050551

EVOGENE LTD.

(EVGN)
  Report
End-of-day quote TEL AVIV STOCK EXCHANGE  -  05-18
3.005 ILS   -1.12%
05/17Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference - Evogene
AQ
05/12Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result(TM) for the 2022 Spring Wheat Growing Season - Evogene
AQ
05/11EVOGENE : Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™ for the 2022 Spring Wheat Growing Season
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evogene : Canonic Company Presentation

01/18/2022 | 07:25am EDT

CULTIVATED by SCIENCE

A subsidiary of

January 2022

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

All right reserved to Canonic LTD.

INTRODUCTION

OUR

VISION

43

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect

All right reserved to Canonic LTD.

Global

Cannabis

Market

46.8

43

38

32

26

20.4

Source: Arcview Market Research/BDSA

All right reserved to Canonic LTD.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Evogene Ltd. published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 12:24:00 UTC.


© Publicnow 2022
All news about EVOGENE LTD.
05/17Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference - Evogene
AQ
05/12Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result(TM) for the 2..
AQ
05/11EVOGENE : Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™..
PU
05/10Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2..
AQ
04/26EVOGENE : AgPlenus Investor Presentation - Form 6-K
PU
04/26EVOGENE : AgPlenus Investor Presentation
PU
04/14Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Res..
AQ
04/13Evogene Subsidiary Biomica Signs Microbiome Clinical Research Deal With Sheba Medical C..
MT
03/31EVOGENE : Other Report or Announcement
PU
03/23Evogene Ltd. Announces Executive Changes
CI
More news
Analyst Recommendations on EVOGENE LTD.
More recommendations
Financials (USD)
Sales 2022 2,52 M - -
Net income 2022 -30,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 36,6 M 36,6 M -
Capi. / Sales 2022 14,5x
Capi. / Sales 2023 2,05x
Nbr of Employees 137
Free-Float 93,9%
Chart EVOGENE LTD.
Duration : Period :
Evogene Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOGENE LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Ofer Haviv Chief Financial & Operational Officer
Yaron Eldad Chief Financial Officer
Sarit Firon Chairman
Mark Kapel Chief Technology Officer
Eyal Emmanuel Vice President-Corporate Strategy
Sector and Competitors
1st jan.Capi. (M$)
EVOGENE LTD.-44.09%37
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524